Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the safety and efficacy of a 0.5% ivermectin cream to a placebo in subjects infested with head lice when used in an "at home" environment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 0.5% ivermectin cream | Experimental |
| |
| vehicle control | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ivermectin cream | Drug | Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Treatment Success Following Treatment With Either Ivermectin or Placebo (Vehicle Control) | Treatment success was defined as the absence of live lice and was determined by visual examination of hair and scalp by a trained evaluator. | Days 2 up to Day 15 post-treatment |
| Number of Participants Reporting Adverse Events Post-Treatment With Either Ivermectin or Placebo (Vehicle Control) | Day 1 up to Day 28 post-application | |
| Summary of the Reported Skin/Scalp Irritations Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Participants skin/scalp irritations were assessed before treatment (Day 1) and Post-treatment with either Ivermectin or placebo by a trained evaluator. Severe scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - Large areas of the scalp are red; Severe Excoriation: Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp. | Day 1 up to Day 15 post-application |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Sanofi Topaz | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cactus Kids Pediatrics | Yuma | Arizona | 85364 | United States | ||
| Impact Clinical Trials |
A total of 247 of the 264 randomized participants who met the inclusion and exclusion criteria received treatment in the study.
Participants were enrolled and treated from 13 October 2009 to 02 December 2009 in 12 US clinical centers.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 0.5% Ivermectin | Participants received a single application of Ivermectin cream on Day 1. |
| FG001 | Placebo (Vehicle Control) | Participants received a single application of vehicle control cream on Day 1. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| vehicle control | Drug | Up to 4 ounces of vehicle control applied to the hair and scalp on day 1 |
|
| Los Angeles |
| California |
| 90057 |
| United States |
| Lice Cleanique, LLC | Delray Beach | Florida | 33484 | United States |
| Hill-Top Research Corp | St. Petersburg | Florida | 33710 | United States |
| LSRN | West Palm Beach | Florida | 33407 | United States |
| Minnesota Clinical Study Center | Fridley | Minnesota | 55432 | United States |
| Lovelace Scientific Resources, Inc. | Albuquerque | New Mexico | 87108 | United States |
| Haywood Pediatric Adolescent Medicine Group, PA | Clyde | North Carolina | 28721 | United States |
| Hill Top Research Corp. | Miamiville | Ohio | 45147 | United States |
| LSRN | Nashville | Tennessee | 37206 | United States |
| Northeast Houston Pediatric Clinic | Houston | Texas | 77015 | United States |
| Virgina Clinical Research, Inc. | Norfolk | Virginia | 23507 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 0.5% Ivermectin | Participants received a single application of Ivermectin cream on Day 1. |
| BG001 | Placebo (Vehicle Control) | Participants received a single application of vehicle control cream on Day 1. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With Treatment Success Following Treatment With Either Ivermectin or Placebo (Vehicle Control) | Treatment success was defined as the absence of live lice and was determined by visual examination of hair and scalp by a trained evaluator. | Treatment success was assessed in the Intent-to-treat population. Any participant with live lice on or after Day 2 received an FDA approved head lice treatment and was classified as a treatment failure, imputed as such for remaining assessments. | Posted | Number | Percent of Participants | Days 2 up to Day 15 post-treatment |
|
|
| ||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants Reporting Adverse Events Post-Treatment With Either Ivermectin or Placebo (Vehicle Control) | Adverse events were assessed in the Intent-to-treat (Safety) population. | Posted | Number | Participants | Day 1 up to Day 28 post-application |
|
| ||||||||||||||||||||||||||||||||||||||
| Primary | Summary of the Reported Skin/Scalp Irritations Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control) | Participants skin/scalp irritations were assessed before treatment (Day 1) and Post-treatment with either Ivermectin or placebo by a trained evaluator. Severe scalp irritations were defined as follows: Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - Large areas of the scalp are red; Severe Excoriation: Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp. | Local tolerability was assessed in the Intent-to-treat (Safety) population. | Posted | Number | Participants | Day 1 up to Day 15 post-application |
|
|
Adverse event data were collected form Day 1 up to Day 28 post-treatment with either Ivermectin or Placebo
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 0.5% Ivermectin | Participants received a single application of Ivermectin cream on Day 1. | 0 | 192 | 8 | 192 | ||
| EG001 | Placebo (Vehicle Control) | Participants received a single application of vehicle control cream on Day 1. | 0 | 55 | 4 | 55 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Excoriation | Injury, poisoning and procedural complications | MedDRA 10.1 | Non-systematic Assessment |
|
Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Director | Sanofi Topaz | RegistryContactUs@sanofipasteur.com |
| >=65 years |
|
| Male |
|
| Day 15 (N = 185, 54) |
|
|
|